HeartBeam Inc. (NASDAQ: BEAT) announced it will host a conference call on August 13 at 4:30 p.m. ET to discuss financial results for the second quarter ended June 30, 2026, and provide updates on its strategy to accelerate global adoption of its ambulatory ECG signal platform. The call will be led by Executive Chairman Richard Ferrari, President and Founder Branislav Vajdic, and Chief Financial Officer Timothy Cruickshank, and will include a question-and-answer session following prepared remarks.
The company, a medical technology firm focused on cardiac care, is developing the first cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. This platform is designed for portable use outside medical facilities, enabling physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care. HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and its 12-lead ECG synthesis software was cleared in December 2025, as detailed in the company's cleared indications for use at https://www.heartbeam.com/indications.
The upcoming call comes as HeartBeam seeks to expand its footprint in the cardiac monitoring market, leveraging its patented technology. The company holds over 20 issued patents related to its technology enablement. The second-quarter results and strategic updates will be closely watched by investors and industry observers for insights into commercialization progress and market adoption. Additional information about the company and its latest news can be found in its newsroom at https://ibn.fm/BEAT.
HeartBeam's platform represents a shift from traditional ECG monitoring, which often requires bulky equipment or multiple leads connected to a central device. By synthesizing 3D signals into a standard 12-lead ECG, the technology aims to provide comprehensive cardiac data in a more convenient, patient-friendly format. The FDA clearances have positioned the company to target both arrhythmia assessment and broader ECG applications, potentially reducing the need for in-clinic visits and enabling earlier detection of cardiac issues.
The conference call will provide an opportunity for management to address questions about the company's financial health, operational milestones, and strategic direction. As the company navigates the competitive landscape of cardiac diagnostics, its progress in securing partnerships, reimbursement codes, and clinical adoption will be key factors in its long-term success. The second-quarter results will offer a snapshot of revenue, expenses, and cash position, while the strategic update may outline plans for market expansion, product enhancements, or regulatory submissions in other regions.
